# Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone

> **NCT00396227** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 2665 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** vildagliptin
- **DRUG:** thiazolidinedione (TZD)

## Key facts

- **NCT ID:** NCT00396227
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2007-10
- **Final completion:** —
- **Target enrollment:** 2665 (ACTUAL)
- **Last updated:** 2016-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00396227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00396227, "Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00396227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*